BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
119.68
+1.36 (+1.15%)
At close: 4:00PM EDT

119.68 0.00 (0.00%)
After hours: 5:54PM EDT

Stock chart is not supported by your current browser
Previous Close118.32
Open119.20
Bid119.78 x 1300
Ask119.84 x 900
Day's Range117.35 - 120.77
52 Week Range87.49 - 189.31
Volume697,214
Avg. Volume476,651
Market Cap6.597B
Beta (3Y Monthly)3.06
PE Ratio (TTM)N/A
EPS (TTM)-11.35
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est175.44
Trade prices are not sourced from all markets
  • Why This Biotech's Approved Gene Therapy Won't Launch Until 2020
    Investor's Business Daily2 days ago

    Why This Biotech's Approved Gene Therapy Won't Launch Until 2020

    Bluebird Bio stock dipped Tuesday after an analyst noted manufacturing hiccups will prevent the biotech company from selling its gene therapy in Europe and the U.S. until 2020 and 2021, respectively.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about bluebird bio Inc.

    bluebird bio Inc NASDAQ/NGS:BLUEView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for BLUE with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting BLUE. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BLUE are favorable, with net inflows of $3.11 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is bluebird bio Inc (BLUE) A Good Stock To Buy?
    Insider Monkey3 days ago

    Is bluebird bio Inc (BLUE) A Good Stock To Buy?

    As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]

  • Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?
    Motley Fool5 days ago

    Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?

    Following European approval earlier this month, bluebird bio announced its beta-thalassemia gene therapy will launch with a sky-high price tag.

  • Barrons.com6 days ago

    Bluebird Bio’s Gene Therapy Is $1.8 Million Per Patient. The Stock Is Falling.

    (BLUE) will sell a gene-therapy treatment for the disease beta-thalassemia for $1.8 million per patient, but the money won’t start coming in as soon as expected. The drug, Zynteglo—the second-most-expensive in the world, according to The Wall Street Journal—received conditional marketing authorization from the European Union early this month. The treatment has yet to be approved by the Food and Drug Administration.

  • Bluebird prices gene therapy in Europe at $1.8M over 5 years
    American City Business Journals6 days ago

    Bluebird prices gene therapy in Europe at $1.8M over 5 years

    Th Cambridge biotech set a price tag of $1.8 million spread over five years (315,000 euros per year, or the equivalent of $356,000 annually) for its first commercial drug on Friday, for which it received approval to sell in Europe last week.

  • Business Wire6 days ago

    bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress

    Up to 3.8 years of transfusion independence in Phase 1/2 Northstar study in patients with TDT who do not have a β0/β0 genotype

  • Business Wire6 days ago

    bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress

    In patients who were at least six months post-treatment with LentiGlobin for SCD, median level of abnormal sickle hemoglobin was reduced to ≤50 percent of total Hb

  • Financial Times6 days ago

    Bluebird Bio prices gene therapy at nearly $1.8m

    Bluebird Bio plans to price a new gene therapy for people with an inherited blood disorder at almost $1.8m per patient, and will try to persuade European healthcare systems to shell out for it by promising to only seek full payment if it works. Healthcare systems will pay an initial instalment of €315,000 but will only pay more instalments if the treatment helps the patient avoid blood transfusions. The Boston-based biotech start-up’s drug is part of a class of new transformative therapies that need to be administered only once and apply to a small patient population.

  • Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license
    American City Business Journals6 days ago

    Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license

    Errant Gene Therapeutics claims in a new lawsuit that local venture capital firm Third Rock Ventures and bluebird bio CEO Nick Leschly worked to hinder its drug development efforts so it could obtain a key part of its intellectual property.

  • bluebird bio (NASDAQ:BLUE) Shareholders Have Enjoyed An Impressive 223% Share Price Gain
    Simply Wall St.8 days ago

    bluebird bio (NASDAQ:BLUE) Shareholders Have Enjoyed An Impressive 223% Share Price Gain

    While bluebird bio, Inc. (NASDAQ:BLUE) shareholders are probably generally happy, the stock hasn't had particularly...

  • Business Wire14 days ago

    bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding βA-T87Q-globin gene) Approval

    To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the event. bluebird bio is pioneering gene therapy with purpose.

  • Life sciences VC firm Third Rock raises $770M in its largest round ever
    American City Business Journals14 days ago

    Life sciences VC firm Third Rock raises $770M in its largest round ever

    One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.

  • bluebird's Zynteglo Gets EU Conditional Marketing Approval
    Zacks16 days ago

    bluebird's Zynteglo Gets EU Conditional Marketing Approval

    bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype.

  • It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy
    Motley Fool16 days ago

    It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy

    European regulators have signed off on the biotech's revolutionary gene therapy for beta-thalassemia.

  • Why Is Bluebird (BLUE) Down 15.1% Since Last Earnings Report?
    Zacks19 days ago

    Why Is Bluebird (BLUE) Down 15.1% Since Last Earnings Report?

    Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire20 days ago

    bluebird bio Announces Investor Events in June

    To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully.

  • Save the Date: 11 Biotech Stocks to Put on Your Radar
    Kiplinger21 days ago

    Save the Date: 11 Biotech Stocks to Put on Your Radar

    This is the time of year when stocks are sleepy at best, and at worst, prone to pullbacks.That's not necessarily true of all equities, however. Some groups are very active and perform quite well in the summer months. Pharmaceutical stocks - and especially biotech stocks - fare pretty well this time of year.Part of that cyclical strength stems from how the Food and Drug Administration schedules key decision-making dates for new drugs. Another part of it may be the result of recurring industry conferences, where many drug-development updates are unveiled.Here are 11 biotech stocks and pharmaceutical companies to watch over the next few months. Because biotechnology companies' shares tend to hinge heavily on product updates, this seasonal tide of news could move their respective stocks well before (and even long after) the day the news is posted. Just be cautious; smaller biotechnology stocks with one or just a couple of trial products can move drastically on new data - for better or for worse. SEE ALSO: 20 Great Stocks That You Haven't Heard Of

  • Marshall Wace’s Latest Moves
    Insider Monkey26 days ago

    Marshall Wace’s Latest Moves

    Back in 1997, Paul Marshall and Ian Wace launched their own hedge fund called Marshall Wace. The fund is headquartered in London, England while providing additional offices in New York, and Hong Kong. The fund’s investment philosophy combines quantitative strategies with basic investment principles for the purpose of delivering strong returns to its clients. Its […]